IONIS PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
IONS$28.19-9.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · Additional · Accumulated Other · Total | ||||||
|---|---|---|---|---|---|---|
| Description | Shares | Amount | Paid in Capital | Comprehensive Loss | Accumulated Deficit | Stockholders' Equity |
| Balance at December 31, 2022 | 142,058 | $142 | $2,059,850 | $(57,480) | $(1,429,625) | $572,887 |
| Net loss | - | - | - | - | (366,286) | (366,286) |
| Change in unrealized gains, net of tax | - | - | - | 24,484 | - | 24,484 |
| Foreign currency translation | - | - | - | 351 | - | 351 |
| Issuance of common stock in connection with employee stock plans, net | 2,283 | 2 | 49,439 | - | - | 49,441 |
| Stock-based compensation expense | - | - | 105,809 | - | - | 105,809 |
| Balance at December 31, 2023 | 144,341 | $144 | $2,215,098 | $(32,645) | $(1,795,911) | $386,686 |
| Net loss | - | - | - | - | (453,897) | (453,897) |
| Change in unrealized gains, net of tax | - | - | - | 2,107 | - | 2,107 |
| Foreign currency translation | - | - | - | (273) | - | (273) |
| Issuance of common stock in connection with employee stock plans, net | 2,068 | 2 | 33,607 | - | - | 33,609 |
| Issuance of public common stock, net | 11,500 | 12 | 489,108 | - | - | 489,120 |
| Stock-based compensation expense | - | - | 130,999 | - | - | 130,999 |
| Balance at December 31, 2024 | 157,909 | $158 | $2,868,812 | $(30,811) | $(2,249,808) | $588,351 |
| Net loss | - | - | - | - | (381,387) | (381,387) |
| Change in unrealized gains, net of tax | - | - | - | 4,828 | - | 4,828 |
| Foreign currency translation | - | - | - | 702 | - | 702 |
| Issuance of common stock in connection with employee stock plans, net | 5,396 | 5 | 192,599 | - | - | 192,604 |
| Stock-based compensation expense | - | - | 135,664 | - | - | 135,664 |
| Inducement related to repurchase of 0 percent convertible senior notes due 2026 | - | - | (51,673) | - | - | (51,673) |
| Balance at December 31, 2025 | 163,305 | $163 | $3,145,402 | $(25,281) | $(2,631,195) | $489,089 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.